home / stock / ivevf / ivevf news

IVEVF News and Press, Inventiva SA From 05/26/23

Stock Information
Company Name: Inventiva SA
Stock Symbol: IVEVF
Market: OTC
Website: inventivapharma.com
Menu
IVEVF IVEVF Quote IVEVF Short IVEVF News IVEVF Articles IVEVF Message Board
Get IVEVF Alerts

News, Short Squeeze, Breakout and More Instantly...
IVEVF - Results of the votes of the Combined Shareholders' General Meeting of May 25, 2023

Daix (France), Long Island City (New York, United States), May 26, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other...
IVEVF - Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a Sino Biopharm’s subsidiary, receives IND approval from the NMPA to initiate the clinical development in mainland China of lanifibranor in NASH Sino Biopharm will participate in the ongoing NATiV3 Phase III trial which, if positive, is...

IVEVF - Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 25 May 2023

Daix, 25 May 2023 Pursuant to Article 241-2 of the AMF General Regulations ( Règlement Général de l’Autorité des marchés financiers ), the purpose of this description is to present the objectives and terms of the Company’s share repurchase program ...

IVEVF - Inventiva reports 2023 First Quarter Financial Information¹ and provides a corporate update

Cash and cash equivalents at €56.3 million, short-term deposits at €0.7 million 2 , and long term deposit at €9.3 million 3 as of March 31, 2023, compared to €86.7 million, €1.0 million and €0.7 million as of December 31, 2022, respectively Im...
IVEVF - Inventiva S.A. (IVA) 2022 Full Year Results Earnings Call Transcript

2023-03-30 13:19:05 ET Inventiva S.A. (IVA) 2022 Full Year Results Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Frédéric Cren – Chief Executive Officer Jean Volatier – Chief Financial Officer Michael Cooreman &#x...

IVEVF - Inventiva announces filing of its 2022 Universal Registration Document and 2022 Annual Report on Form 20-F

Daix (France), Long Island City (New York, United States) , March 30, 2023 Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (N...

IVEVF - Inventiva reports its 2022 full-year results

Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021 Inventiva entered into a license and collaboration agreement with Sino Biop...
IVEVF - Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results

Daix (France), Long Island City (New York, United States) , March 23 , 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the t...

IVEVF - Correction: Inventiva reports preliminary financial results for Full-Year 2022¹

Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of p...

IVEVF - Inventiva reports preliminary financial results for Full-Year 2022¹

Daix (France), Long Island City (New York, United States), February 14, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of p...
Previous 10 Next 10